权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Chemoprevention of Colorectal Cancer by Aldose Reductase Inhibition

通过抑制醛糖还原酶化学预防结直肠癌

基本信息

批准号：
9038314
负责人：
SATISH K SRIVASTAVA
金额：
$ 31.2万
依托单位：
UNIVERSITY OF TEXAS MED BR GALVESTON
依托单位国家：
美国
项目类别：
财政年份：
2007
资助国家：
美国
起止时间：
2007-12-01 至 2018-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9038314
关键词：
4 hydroxynonenal Abbreviations Aberrant crypt foci Ablation Adhesions Aldehyde Reductase Aldehydes Antineoplastic Agents Apoptosis Apoptotic Azoxymethane Beds Biopsy Biopsy Specimen Cancer Cell Growth Carrier Proteins Cause of Death Cell Death Cell model Cell surface Cessation of life Cetuximab Chemoprevention Chemopreventive Agent Clinical Protocols Clinical Trials Colon Carcinoma Colorectal Cancer Cyclophosphamide Cytotoxic agent Development Diabetic Neuropathies Dinoprostone Drug Transport Enzymes Fluorouracil Foundations Functional disorder Funding Glutathione Goals Growth HCT116 Cells HT29 Cells Health Homeostasis Human Implant In Situ Hybridization In Vitro Inflammatory Isoenzymes Kidney Lead Lesion Lipid Peroxidation Lipids Liver Lung MAP Kinase Gene Malignant Neoplasms Mediating Mediator of activation protein Metastatic Neoplasm to the Liver Microscopic Modeling Molecular Mus NF-kappa B Neoplasm Metastasis Nude Mice Operative Surgical Procedures Oxidation-Reduction Oxidative Stress Participant Pathology Pathway interactions Pharmaceutical Preparations Phase III Clinical Trials Play Predisposition Preventive Preventive measure Protein Kinase C Publishing Reactive Oxygen Species Regulation Role SW480 Sampling Signal Pathway Signal Transduction Small Interfering RNA Spleen Staging TP53 gene Testing Therapeutic Time Tissues Translating Transplantation Xenograft procedure angiogenesis base bench to bedside cancer cell cancer stem cell carcinogenesis chemokine colon cancer cell line colon carcinogenesis cytokine cytotoxic enzyme pathway fidarestat histopathological examination human DNA in vivo inflammatory marker inhibitor/antagonist innovation lymph nodes migration mortality mouse model novel novel therapeutics oxaliplatin polyol prevent translational study tumor growth tumor progression

项目摘要

DESCRIPTION (provided by applicant): We have recently demonstrated that aldose reductase (AR), an enzyme that catalyzes the reduction of reactive oxygen species-induced lipid peroxidation-derived lipid aldehydes and their glutathione (GSH)- conjugates (GS-LDAs), is an essential mediator of oxidative stress-induced carcinogenic signals. Our results from the previous project period have shown that inhibition of AR prevents the growth of human colon cancer cells by inhibiting the expression of NF-κB-dependent inflammatory markers. We have also shown that inhibition of AR prevents growth of human colon cancer cells in nude mouse xenografts, as well as azoxymethane-induced aberrant crypt foci formation in a mouse model. Further, we have also shown that inhibition of AR prevents colon cancer metastasis by preventing cancer cell invasion, migration and adhesion, as well as angiogenesis. Although we have shown that AR-catalyzed reduced products of GS-LDAs, such as GS-DHN, transduce carcinogenic signals downstream to protein kinase C (PKC), the molecular mechanisms that regulate cellular redox homeostasis leading to carcinogenesis are not clearly understood. We hypothesize that lipid aldehydes and GS-conjugates mediate anti-carcinogenic and pro-carcinogenic signaling cascades that lead to colon cancer growth and metastasis. Our goal in this project is to determine the mechanisms by which AR-catalytic activity plays a critical role in the regulation of colon carcinogenesis using human colon cancer cells, isolated human colon cancer stem cells in vitro, as well as in vivo orthotopic mouse models. Our long-term goal is to develop inhibitors of AR as safe and effective preventive measures for colorectal cancer growth and metastasis. Our specific aims are to: 1) determine how glutathione-lipid aldehydes (GS-LDAs) regulate NF-kB and Nrf-2 pathways that mediate CRC cell growth/death; 2) elucidate how AR inhibition prevents growth and metastasis of human CRC biopsy samples and colon cancer stem cells implanted in athymic nude mice; and 3) determine how AR inhibition prevents the survival of colon cancer stem cells. Completion of this project will elucidate the molecular mechanisms by which AR regulates cellular redox homeostasis, carcinogenesis and tumor growth and metastasis, and lay the foundation for the use of AR inhibitors as novel chemopreventive drugs for colorectal cancer.

描述（由申请人提供）：我们最近证明醛糖还原酶（AR）是一种催化活性氧诱导的脂质过氧化衍生的脂质醛及其谷胱甘肽（GSH）-缀合物（GS-LDA）还原的酶，是氧化应激诱导的致癌信号的重要介质。我们上一个项目期间的结果表明，抑制 AR 通过抑制 AR 的表达来阻止人类结肠癌细胞的生长。 NF-κB 依赖性炎症标志物。我们还表明，抑制 AR 可以防止裸鼠异种移植物中人类结肠癌细胞的生长，以及在小鼠模型中氧化偶氮甲烷诱导的异常隐窝病灶形成。此外，我们还表明，抑制 AR 可通过阻止癌细胞侵袭、迁移和粘附以及血管生成来预防结肠癌转移。尽管我们已经证明 AR 催化的 GS-LDA 还原产物（例如 GS-DHN）可将致癌信号转导至蛋白激酶 C (PKC) 下游，但调节细胞氧化还原稳态导致致癌的分子机制尚不清楚。我们假设脂醛和 GS 结合物介导抗癌和促癌信号级联反应，导致结肠癌生长和转移。我们这个项目的目标是确定 AR 催化活性在使用人结肠癌细胞、体外分离的人结肠癌干细胞以及体内原位小鼠模型来调节结肠癌发生。我们的长期目标是开发AR抑制剂作为结直肠癌生长和转移的安全有效的预防措施。我们的具体目标是：1) 确定谷胱甘肽脂醛 (GS-LDA) 如何调节介导 CRC 细胞生长/死亡的 NF-kB 和 Nrf-2 通路； 2）阐明AR抑制如何阻止人类CRC活检样本和植入无胸腺裸鼠的结肠癌干细胞的生长和转移； 3) 确定 AR 抑制如何阻止结肠癌干细胞的存活。该项目的完成将阐明AR调节细胞氧化还原稳态、致癌及肿瘤生长和转移的分子机制，为AR抑制剂作为结直肠癌新型化学预防药物奠定基础。